Cytek Net Income From Continuing Ops from 2010 to 2026
| CTKB Stock | USD 4.01 0.01 0.25% |
Net Loss | First Reported 2020-06-30 | Previous Quarter -5.5 M | Current Value -44.1 M | Quarterly Volatility 10.7 M |
Macro event markers
Use the financial statements timeline for Cytek Biosciences to frame performance drivers and balance sheet structure. Track Tax Provision of 38.5 M, Net Interest Income of 2.9 M or Interest Income of 4 M and ratios such as Price To Sales Ratio of 3.04, Dividend Yield of 0.0 or PTB Ratio of 1.98 to align performance context with Cytek Biosciences Valuation and Volatility.
Cytek | Net Income From Continuing Ops | Build AI portfolio with Cytek Stock |
Analyzing Cytek Biosciences's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Cytek Biosciences's current valuation and future prospects.
Latest Cytek Biosciences' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Cytek Biosciences over the last few years. It is Cytek Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Cytek Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | -17,155,062 | |
| Geometric Mean | 15,297,318 | |
| Coefficient Of Variation | -120.92 | |
| Mean Deviation | 11,228,344 | |
| Median | -16,827,000 | |
| Standard Deviation | 20,743,543 | |
| Sample Variance | 430.3T | |
| Range | 86M | |
| R-Value | -0.25 | |
| Mean Square Error | 429.3T | |
| R-Squared | 0.06 | |
| Significance | 0.32 | |
| Slope | -1,044,663 | |
| Total Sum of Squares | 6884.7T |
Cytek Net Income From Continuing Ops History
Stock Overview, Methodology & Data Sources
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. Cytek Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 555 people. Operational efficiency and capital allocation discipline are central to the long-run profile of Cytek Biosciences. The company is currently operating at a loss. Cytek Biosciences has a market cap of 514.2 M, ROE of -18.05%.
Methodology
Unless otherwise specified, financial data for Cytek Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cytek (USA Stocks:CTKB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Cytek Biosciences may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Vlad Skutelnik - Macroaxis ContributorAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Cytek Stock Analysis
Understanding Cytek Biosciences typically begins with financial statements and long-term trend review. Ratios and trend metrics help frame Cytek Biosciences' operating context. Below are reports that help frame Cytek Biosciences Stock in context:Use Cytek Biosciences Correlation to compare Cytek Biosciences against competitors. The view adds relative comparison context. Discover how to invest in Cytek Stock by reading our How to Buy Cytek Stock guide.Analysis related to Cytek Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Quarterly Earnings Growth 0.735 | Earnings Share -0.52 | Revenue Per Share | Quarterly Revenue Growth 0.081 | Return On Assets |
Cytek Biosciences's market price can diverge from book value, the accounting figure shown on Cytek's balance sheet. Cytek Biosciences' market capitalization is 514.2 M. A P/B ratio of 1.5 indicates the market values Cytek Biosciences above its accounting book value. Enterprise value stands at 276.41 M. Value and price for Cytek Biosciences are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
It is useful to distinguish Cytek Biosciences' value from its trading price, which are computed with different methods. For Cytek Biosciences, key inputs include a P/B ratio of 1.5, a profit margin of -33.02%, ROE of -18.05%, and revenue of 201.49 M. Market price reflects the current exchange level formed by active bids and offers.